| Empower Speech Llc | |
|
5713 Phillips Rd, Gibsonia, PA 15044 | |
| (724) 355-8062 | |
| Not Available |
| Full Name | Empower Speech Llc |
|---|---|
| Type | Facility |
| Speciality | Speech-language Pathologist |
| Location | 5713 Phillips Rd, Gibsonia, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104588235 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Empower Speech Llc 410 Northtowne Sq # 215, Gibsonia, PA 15044-7525 Ph: (724) 355-8062 | Empower Speech Llc 5713 Phillips Rd, Gibsonia, PA 15044 Ph: (724) 355-8062 |
News Archive
Scientists from the Florida campus of The Scripps Research Institute have identified a molecular interaction between a structural hepatitis C virus protein (HCV) and a protein critical to viral replication. This new finding strongly suggests a novel method of inhibiting the production of the virus and a potential new therapeutic target for hepatitis C drug development.
pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has submitted a New Drug Application to the U.S. Food and Drug Administration for Iluvien for Diabetic Macular Edema.
Researchers have modeled the effect of the different types of social distancing implemented in Australia's greater Melbourne area in response to the county's second wave of coronavirus disease 2019 (COVID-19) cases. They found implementing stricter lockdowns in the beginning before the rapid rise in cases works best. The team's findings have been made available on the preprint server, medRxiv*.
Arterial Remodeling Technologies ("ART") announced today that it has closed on a new venture financing round of $8.5 million from existing investors Matignon Technologies and Amundi Private Equity Funds, along with new investor InnoBio Fund managed by CDC Entreprises. Total investment in the Company is now $17 million.
Onyx Pharmaceuticals, Inc. today announced results from the Phase 3 trial GRID (GIST – Regorafenib in Progressive Disease) evaluating the investigational compound regorafenib (BAY 73-4506), a Bayer-owned compound, for the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib.
› Verified 5 days ago
Jessica Rae Kennelly, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5316 William Flynn Hwy, Gibsonia, PA 15044 Phone: 724-444-5333 | |
Beth Mcswaney, MS CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5827 Meridian Rd, Gibsonia, PA 15044 Phone: 724-443-0700 Fax: 724-443-4410 | |
Megan Ballantyne, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5316 William Flynn Hwy, Gibsonia, PA 15044 Phone: 724-444-5333 | |
Mrs. Maureen Lynn Weckerly, MS CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5827 Meridian Road, Gibsonia, PA 15044 Phone: 724-443-0700 Fax: 724-443-4410 | |
Katie Labrozzi, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 806 Oxford Ct, Gibsonia, PA 15044 Phone: 814-574-4242 | |
Ashley B Morrison, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 111 Carters Grove Dr, Gibsonia, PA 15044 Phone: 724-766-5366 |